Sign up to save your podcasts
Or
Share Abbott Laboratories (ABT), 2024 Q4 earnings digest
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Abbott Laboratories (ABT), 2024 Q4 earnings digest
$ABT just released its Q4 2024 earnings, showcasing a strong quarter with 10% sales growth and 13% EPS growth. Highlights include strong cash flow of $8.5 billion and robust performance across all segments, particularly Diabetes Care +23% growth.
For 2025, Abbott forecasts a solid 7.5-8.5% organic sales growth and adjusted EPS in the range of $5.05 to $5.25, indicating double-digit growth potential. However, risks linger regarding foreign exchange impacts and tax rates.
View all episodes
By ValueVerge$ABT just released its Q4 2024 earnings, showcasing a strong quarter with 10% sales growth and 13% EPS growth. Highlights include strong cash flow of $8.5 billion and robust performance across all segments, particularly Diabetes Care +23% growth.
For 2025, Abbott forecasts a solid 7.5-8.5% organic sales growth and adjusted EPS in the range of $5.05 to $5.25, indicating double-digit growth potential. However, risks linger regarding foreign exchange impacts and tax rates.